Exploring The Potential Therapeutic Applications of KCNK18 (TRESK)

Target Name: KCNK18

NCBI ID: G338567

KCNK18

Exploring The Potential Therapeutic Applications of KCNK18 (TRESK)

KCNK18 (TRESK) is a protein that is expressed in various tissues of the body, including the brain, heart, and skeletal muscles. It is a member of the potassium channel subfamily 18, which is a family of proteins that are involved in the regulation of electrical activity in cells.

The function of KCNK18 (TRESK) is not well understood, but it is believed to play a role in the regulation of muscle contractions and heart rate. It is also suggested to be involved in the regulation of pain perception and neurotransmitter release.

KCNK18 (TRESK) has been identified as a potential drug target in the treatment of various neurological and psychiatric disorders, including epilepsy, schizophrenia, and Alzheimer's disease. Studies have shown that modulating the activity of KCNK18 (TRESK) has the potential to treat these disorders by reducing the activity of neurons that are involved in the pathophysiology of these conditions.

One approach to target KCNK18 (TRESK) is to use small molecules that can modulate its activity. One such approach is the use of pharmacological agents that can bind to KCNK18 (TRESK) and alter its activity.

Another approach to target KCNK18 (TRESK) is to use genetic modifiers that can alter its expression levels. This can be done by using CRISPR-Cas9 technology to introduce mutations into the gene that encodes KCNK18 (TRESK) and then using these mutations to create a strain of the protein that has altered activity.

In addition to these approaches, researchers are also exploring the use of Exercise as a form of therapy for modulating KCNK18 (TRESK) activity. Exercise has been shown to increase the activity of KCNK18 (TRESK) in muscle cells, which could potentially lead to increased muscle contractions and improved muscle performance.

Overall, KCNK18 (TRESK) is a protein that is of interest as a drug target due to its potential involvement in the regulation of muscle and neural function. Further research is needed to fully understand its function and the potential benefits of targeting it.

Protein Name: Potassium Two Pore Domain Channel Subfamily K Member 18

Functions: Outward rectifying potassium channel. Produces rapidly activating outward rectifier K(+) currents. May function as background potassium channel that sets the resting membrane potential. Channel activity is directly activated by calcium signal. Activated by the G(q)-protein coupled receptor pathway. The calcium signal robustly activates the channel via calcineurin, whereas the anchoring of 14-3-3/YWHAH interferes with the return of the current to the resting state after activation. Inhibited also by arachidonic acid and other naturally occurring unsaturated free fatty acids. Channel activity is also enhanced by volatile anesthetics, such as isoflurane. Appears to be the primary target of hydroxy-alpha-sanshool, an ingredient of Schezuan pepper. May be involved in the somatosensory function with special respect to pain sensation (By similarity)

The "KCNK18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNK18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets